|
Compact Navigation System for CT-guided Needle Interventions
|
1UT1CA224886-01A1
|
$149,927
|
$149,927
|
TSE, TSZ HO
|
3T TECHNOLOGIES, LLC
|
|
Therapeutic peptide for hepatocellular carcinoma
|
1R43CA232947-01
|
$299,983
|
$299,983
|
PANDEY, NIRANJAN
|
ASCLEPIX THERAPEUTICS, LLC
|
|
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
|
5R01CA168912-05
|
$320,588
|
$320,588
|
HE, YUKAI
|
AUGUSTA UNIVERSITY
|
|
TREM-1 and Its Implications to Cancer
|
5R01CA172230-05
|
$315,400
|
$315,400
|
HORUZSKO, ANATOLIJ
|
AUGUSTA UNIVERSITY
|
|
Role of heat shock transcription factor HSF1 in tumoroginesis
|
5R01CA062130-23
|
$556,510
|
$556,510
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
Development of cell-free DNA assays for HCC screening and liquid biopsy
|
5R01CA202769-03
|
$397,877
|
$397,877
|
SU, YING-HSIU
|
BARUCH S. BLUMBERG INSTITUTE
|
|
A New Lab Based Algorithm for HCC Surveillance in Patients with Cirrhosis
|
3R01CA190776-04S1
|
$116,456
|
$116,456
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
A New Lab Based Algorithm for HCC Surveillance in Patients with Cirrhosis
|
5R01CA190776-04
|
$546,636
|
$546,636
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis
|
1R01CA230848-01
|
$442,560
|
$442,560
|
FU, LONING
|
BAYLOR COLLEGE OF MEDICINE
|
|
Risk Stratification for and Early Detection of Liver Cancer
|
1U01CA230997-01
|
$732,726
|
$732,726
|
KANWAL, FASIHA
|
BAYLOR COLLEGE OF MEDICINE
|
|
2/2: UHCOP-DLDCCC alliance: Cancer drug discovery/development and education
|
1P20CA221729-01A1
|
$258,006
|
$100,622
|
MATZUK, MARTIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
$10,699
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
$22,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
$11,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
$288,281
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
De facto Target of Histone Deacetylase Inhibitors
|
5R21CA215591-02
|
$172,369
|
$172,369
|
SUN, ZHENG
|
BAYLOR COLLEGE OF MEDICINE
|
|
MiRNAs in hepatocellular carcinoma development and treatment
|
5R01CA139158-07
|
$410,875
|
$410,875
|
HUANG, WENDONG
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
$50,864
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
$17,300
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
$875
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
$159,995
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S1
|
$3,249,644
|
$162,482
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S2
|
$1,000,000
|
$50,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-05
|
$8,073,787
|
$403,689
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Selenoproteins as targets for cancer prevention
|
5R01CA080946-18
|
$223,000
|
$223,000
|
GLADYSHEV, VADIM
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Integrative genomic framework for dissecting regulatory mechanisms underlying hepatocellular carcinoma
|
5R21CA209940-02
|
$175,001
|
$175,001
|
POCHET, NATHALIE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-28
|
$5,637,954
|
$56,380
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-28S1
|
$249,965
|
$2,500
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Contribution of Gynecologic and Breast Cancer Biospecimens from African American women to HCMI
|
3P30CA043703-28S2
|
$48,000
|
$480
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Imaging Liver Cancer Proliferation
|
5R01CA204373-03
|
$378,195
|
$378,195
|
LEE, ZHENGHONG
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-05
|
$1,187,291
|
$29,682
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Identification of microbial biomarkers for hepatocellular carcinoma in a multi-ethnic population of patients with nonalcoholic fatty liver disease
|
1R21CA225623-01
|
$176,514
|
$176,514
|
HUSSAIN, SHEHNAZ
|
CEDARS-SINAI MEDICAL CENTER
|
|
Gut-Related Markers and Hepatocellular Cancer in a Multi-Ethnic Cirrhotic Cohort
|
5R01CA204145-03
|
$260,399
|
$260,399
|
HUSSAIN, SHEHNAZ
|
CEDARS-SINAI MEDICAL CENTER
|
|
Statin Intervention to Slow the Time to Hepatocellular Carcinoma Recurrence in Cirrhotics Awaiting Liver Transplantation
|
5R01CA218486-02
|
$661,266
|
$661,266
|
HUSSAIN, SHEHNAZ
|
CEDARS-SINAI MEDICAL CENTER
|
|
PROHIBITIN 1 IN LIVER INJURY AND CANCER
|
5R01CA172086-05
|
$312,404
|
$312,404
|
LU, SHELLY
|
CEDARS-SINAI MEDICAL CENTER
|
|
The Development of Novel Mechanistically-based APE/Ref-1 Redox Inhibitors
|
5K08CA179084-05
|
$112,331
|
$56,166
|
YANG, SUN
|
CHAPMAN UNIVERSITY
|
|
The Mechanism of Tumor Formation in Beckwith-Wiedemann Syndrome
|
5K08CA193915-04
|
$140,504
|
$140,504
|
KALISH, JENNIFER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Cold Spring Harbor Laboratory Cancer Research Center
|
2P01CA013106-46A1
|
$4,537,433
|
$1,225,107
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
CSHL Cancer Center Support Grant
|
5P30CA045508-31
|
$4,371,458
|
$612,004
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
Roles and Regulation of wild-type and mutant forms of p53
|
5P01CA087497-17
|
$1,885,586
|
$433,685
|
PRIVES, CAROL
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Engineering of bacterial probiotics for the detection and treatment of hepatocellular carcinoma
|
1F32CA225145-01
|
$59,038
|
$59,038
|
SINGER, ZAKARY
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma
|
1R01CA228483-01A1
|
$634,470
|
$634,470
|
SCHWABE, ROBERT
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Hepatic Stellate Cells and Liver Cancer
|
5R01CA190844-04
|
$356,751
|
$356,751
|
SCHWABE, ROBERT
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
HMGB1 as Link Between Hepatocellular Injury and HCC
|
5R01CA200597-03
|
$443,761
|
$443,761
|
SCHWABE, ROBERT
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S1
|
$120,000
|
$4,800
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S2
|
$60,000
|
$2,400
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant - PDXNet Supplement
|
3P30CA013696-44S3
|
$126,563
|
$5,063
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S4
|
$191,726
|
$7,669
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S5
|
$237,191
|
$9,488
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S6
|
$246,815
|
$9,873
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
Total relevant funding to Liver Cancer for this search: $94,572,867
|